Connection
Thomas Jensen to Cardiovascular Diseases
This is a "connection" page, showing publications Thomas Jensen has written about Cardiovascular Diseases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.201 |
|
|
|
-
Kobo O, Cavender MA, Jensen TJ, Kuhlman AB, Rasmussen S, Verma S. Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis. Diabetes Obes Metab. 2024 Mar; 26(3):1129-1132.
Score: 0.101
-
Crowley MJ, McGuire DK, Alexopoulos AS, Jensen TJ, Rasmussen S, Saevereid HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. Diabetes Care. 2020 09; 43(9):e108-e110.
Score: 0.080
-
Hansen CN, Jensen TJ, Borch-Johnsen K. [Dyslipidemia, diabetes and cardiovascular disease]. Ugeskr Laeger. 2000 Aug 14; 162(33):4367-70.
Score: 0.020